| Dr Brad L Lindsey, MD | |
|
4605 Maccorkle Ave Sw, South Charleston, WV 25309-1311 | |
| (304) 414-4800 | |
| Not Available |
| Full Name | Dr Brad L Lindsey |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 27 Years |
| Location | 4605 Maccorkle Ave Sw, South Charleston, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346236072 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | E2860 (Arkansas) | Secondary |
| 207LP2900X | Anesthesiology - Pain Medicine | 29999 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Logan Regional Medical Center | Logan, WV | Hospital |
| St Francis Hospital | Charleston, WV | Hospital |
| Boone Memorial Hospital | Madison, WV | Hospital |
| Thomas Memorial Hospital | South charleston, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Center For Pain Relief Inc | 3476448457 | 2 |
| Ths Physician Partners Inc | 9537316393 | 135 |
News Archive
Nuance Communications, Inc. announced today that 20 of the Top 25 Connected Healthcare Facilities, as recognized by Health Imaging & IT magazine, use radiology solutions from Nuance.
Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.
A paper co-published by College of Health and Human Services faculty is demonstrating the capability of new technology that allows in-depth analysis of health outcomes amongst different groups. Published in the American Journal of Preventative Medicine, the research outlines a novel approach to studying public health data.
It is well known that oral infection progressively destroys periodontal tissues and is the leading cause of tooth loss in adults. A major goal of periodontal treatment is regeneration of the tissues lost to periodontitis. Unfortunately, most current therapies cannot predictably promote repair of tooth-supporting defects. A variety of regenerative approaches have been used clinically using bone grafts and guiding tissue membranes with limited success.
› Verified 7 days ago
| Entity Name | Center For Pain Relief Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831116375 PECOS PAC ID: 3476448457 Enrollment ID: O20040218000684 |
News Archive
Nuance Communications, Inc. announced today that 20 of the Top 25 Connected Healthcare Facilities, as recognized by Health Imaging & IT magazine, use radiology solutions from Nuance.
Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.
A paper co-published by College of Health and Human Services faculty is demonstrating the capability of new technology that allows in-depth analysis of health outcomes amongst different groups. Published in the American Journal of Preventative Medicine, the research outlines a novel approach to studying public health data.
It is well known that oral infection progressively destroys periodontal tissues and is the leading cause of tooth loss in adults. A major goal of periodontal treatment is regeneration of the tissues lost to periodontitis. Unfortunately, most current therapies cannot predictably promote repair of tooth-supporting defects. A variety of regenerative approaches have been used clinically using bone grafts and guiding tissue membranes with limited success.
› Verified 7 days ago
| Entity Name | Boone Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285686725 PECOS PAC ID: 3375433352 Enrollment ID: O20051111000050 |
News Archive
Nuance Communications, Inc. announced today that 20 of the Top 25 Connected Healthcare Facilities, as recognized by Health Imaging & IT magazine, use radiology solutions from Nuance.
Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.
A paper co-published by College of Health and Human Services faculty is demonstrating the capability of new technology that allows in-depth analysis of health outcomes amongst different groups. Published in the American Journal of Preventative Medicine, the research outlines a novel approach to studying public health data.
It is well known that oral infection progressively destroys periodontal tissues and is the leading cause of tooth loss in adults. A major goal of periodontal treatment is regeneration of the tissues lost to periodontitis. Unfortunately, most current therapies cannot predictably promote repair of tooth-supporting defects. A variety of regenerative approaches have been used clinically using bone grafts and guiding tissue membranes with limited success.
› Verified 7 days ago
| Entity Name | Boone Memorial Hospital Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1639135221 PECOS PAC ID: 3375433352 Enrollment ID: O20061104000273 |
News Archive
Nuance Communications, Inc. announced today that 20 of the Top 25 Connected Healthcare Facilities, as recognized by Health Imaging & IT magazine, use radiology solutions from Nuance.
Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.
A paper co-published by College of Health and Human Services faculty is demonstrating the capability of new technology that allows in-depth analysis of health outcomes amongst different groups. Published in the American Journal of Preventative Medicine, the research outlines a novel approach to studying public health data.
It is well known that oral infection progressively destroys periodontal tissues and is the leading cause of tooth loss in adults. A major goal of periodontal treatment is regeneration of the tissues lost to periodontitis. Unfortunately, most current therapies cannot predictably promote repair of tooth-supporting defects. A variety of regenerative approaches have been used clinically using bone grafts and guiding tissue membranes with limited success.
› Verified 7 days ago
| Entity Name | Ths Physician Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871866806 PECOS PAC ID: 9537316393 Enrollment ID: O20120829000738 |
News Archive
Nuance Communications, Inc. announced today that 20 of the Top 25 Connected Healthcare Facilities, as recognized by Health Imaging & IT magazine, use radiology solutions from Nuance.
Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.
A paper co-published by College of Health and Human Services faculty is demonstrating the capability of new technology that allows in-depth analysis of health outcomes amongst different groups. Published in the American Journal of Preventative Medicine, the research outlines a novel approach to studying public health data.
It is well known that oral infection progressively destroys periodontal tissues and is the leading cause of tooth loss in adults. A major goal of periodontal treatment is regeneration of the tissues lost to periodontitis. Unfortunately, most current therapies cannot predictably promote repair of tooth-supporting defects. A variety of regenerative approaches have been used clinically using bone grafts and guiding tissue membranes with limited success.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brad L Lindsey, MD 4605 Maccorkle Ave Sw, Charleston, WV 25309-1311 Ph: (304) 414-4800 | Dr Brad L Lindsey, MD 4605 Maccorkle Ave Sw, South Charleston, WV 25309-1311 Ph: (304) 414-4800 |
News Archive
Nuance Communications, Inc. announced today that 20 of the Top 25 Connected Healthcare Facilities, as recognized by Health Imaging & IT magazine, use radiology solutions from Nuance.
Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the fifth patient in its ongoing Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of the August 2009 license agreement between Curis and Debiopharm, Curis will receive a $3 million milestone payment from Debiopharm for the achievement of this development objective.
A paper co-published by College of Health and Human Services faculty is demonstrating the capability of new technology that allows in-depth analysis of health outcomes amongst different groups. Published in the American Journal of Preventative Medicine, the research outlines a novel approach to studying public health data.
It is well known that oral infection progressively destroys periodontal tissues and is the leading cause of tooth loss in adults. A major goal of periodontal treatment is regeneration of the tissues lost to periodontitis. Unfortunately, most current therapies cannot predictably promote repair of tooth-supporting defects. A variety of regenerative approaches have been used clinically using bone grafts and guiding tissue membranes with limited success.
› Verified 7 days ago
Dr. Kellee E. Abner, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4605 Maccorkle Ave Sw, South Charleston, WV 25309 Phone: 304-344-0096 Fax: 304-342-4725 | |
Dr. Nayana R. Megha, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4605 Maccorkle Ave Sw, South Charleston, WV 25309 Phone: 304-766-3600 |